Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR070803 + mFOLFOX6 vs GemCap in Adjuvant Pancreatic Cancer
NCT06217042Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of CPO-120 in pancreatic cancer (PC), sponsored by Fudan University. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
CPO-120
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06217042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217042.